"Dicarbonyl protein adduction: plasminogen as a target and metformin as a scavenging therapeutic in type 2 diabetes"
Year Graduated: 2014
Career Type: Industry
Regulatory Specialist, Ecolab, Eagan, MN
Academic & Professional Updates
My graduate dissertation research focuses on the effects of methyglyoxal, a toxic byproduct of glycolysis that is elevated due to hyperglycemia, has in the progression of complications from type-2 diabetes mellitus (T2DM). In particular, I am exploring the role of adduction by methylglyoxal on arginine residues of plasminogen, a critical protein in the fibrinolytic cascade. Additionally, I'm studying a mechanism of the T2DM drug metformin that reduces the amount of circulating methylglyoxal that may ultimately play a role in the reduction in T2DM complications observed in patients on metformin.
B.A., Chemistry (2009)
University of Minnesota, Morris
Honors & Achievements
1. Travel Award SOT Meeting, 2010-11. 2. NIEHS Training Grant - Environmental Toxicology of Human Diseases, 2011 (31). 3. Mary E. Caldwell Memorial Scholarship, 2011-12. 4. ASPET Meeting Travel Award, 2011-12. 5. SOT Award, Second Place, Carl C. Smith Mechanisms Specialty Section, 2012. 6. NIEHS Training Grant - Environmental Toxicology of Human Diseases, 2012 (32). 7. SOT Mechanisms Specialty Section Carl C. Smith Award Honorable Mention, 2013-14. 8. ASPET Graduate Student Best Abstract in Molecular Pharmacology, 2013-14. 9. ASPET Graduate Student Travel Award, 2013-14. 10. NIEHS Training Grant - Environmental Toxicology of Human Diseases, 2013 (33).
1. Owen R. Kinsky, O.R., Hargraves, T.L., Anumol, T. Jacobsen, N.E., Dai, J., Shane A. Snyder, S.A., Monks, T.J. and Lau, S.S. A cyclized imidazolinone derivative is the predominant methylglyoxal scavenging product from the anti-hyperglycemic drug metformin: A potential alternative therapeutic mechanism, Submission to Diabetes.